A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

Phase 1 Recruiting 154 enrolled Coherus Oncology, Inc.

RandomizedParallel-groupOpen-labelTreatment

Summary

The main purpose of this study is to evaluate the safety and preliminary efficacy of CHS-114 in combination with toripalimab and/or other standard of care (SOC) compound(s) in participants with advanced or metastatic solid tumors.

Timeline

Start: 2025-04-01
Primary completion: 2028-01
Completion: 2028-01

Publications

Wang X, Kapoor VN, Chin DJ, Klakamp SL, Baruffaldi F, Mohan JF, Haines R, Dulak A, Panduro M, Ren Y, Masia R, Hill JA, LaVallee TM, Rajasekaran N. CHS-114: An Afucosylated Anti-CCR8 Monoclonal Antibody that Selectively Depletes Intratumoral Treg Cells and Induces Antitumor Immune Responses. Mol Cancer Ther. 2026 May 4;25(5):685-700. doi: 10.1158/1535-7163.MCT-25-0367.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CHS-114	Monoclonal antibody	—	Intravenous
Subject	Cisplatin	Other / unclassified	—	—
Subject	fluorouracil	Small molecule	—	—
Background	Toripalimab	Monoclonal antibody	—	—

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

Summary

Timeline

Publications

Drugs

Indications